Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment of Inflammatory Bowel Disease ("IBD"), today announced that management will participate in the TD Cowen 44th Annual Health Care Conference.
Cameron Turtle, Chief Executive Officer, will participate in the Inflammation & Immunology Corporate Panel Discussion on Tuesday, March 5, 2024, at 2:10 p.m. Eastern time.
To access this webcast, please visit the "Events & Presentations" page within the Investors section of the Spyre website at ir.spyre.com. An archive of the webcast will be available for replay for 30 days following the end of the conference.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23. For more information, visit Spyre's website at www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and LinkedIn
For Investors: Eric McIntyre VP of Finance and Investor Relations Spyre Therapeutics [email protected]
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...
U.S.-based tech startup Iozera, in collaboration with the Government of Morocco, announces an initiative set to transform the AI industry. Iozera has announced the signing of a Memorandum of Understanding (MOU) for the establishment of a pioneering...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...
With a remarkable achievement of 81.556 billion yuan in operating revenue, marking an 11.74% increase from the previous year, and a net profit attributable to shareholders of 7.039 billion yuan, soaring by 27.21%, JA Solar hit historic highs in both...
Leading research and experience management firm Sogolytics will showcase innovations in HR and employee experience at UNLEASH America next week.
"With such a rapid evolution in the world of HR tech, we're seeing some major changes in how employers...